Development of Clinically Translatable PLGA?iLNP Hybrid Nanoparticles for Mutation-Agnostic CFTR mRNA Therapy

• Forschungsstelle: INNOSUISSE
• Projektnummer: 137.048 INNO-LS
• Projekttitel Englisch: Development of Clinically Translatable PLGA?iLNP Hybrid Nanoparticles for Mutation-Agnostic CFTR mRNA Therapy

Schlüsselwörter (Englisch)

Life sciences, Personalised medicine

Abstract (Englisch)

PLGA?ionizable lipid hybrid nanoparticles are developed as a PEG-free pulmonary delivery system for mutation-agnostic CFTR mRNA therapy. The project systematically optimizes hybrid nanoparticle architecture to enable repeat-dose?compatible, clinically translatable CFTR restoration in cystic fibrosis